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on 1.0mg/day dose. Median follow up of patients was:
11.5± 4.13 months (1.0mg dose) and 9.25± 4.78 months
(0.5mg dose). Four of six patients (66%) who received
1mg/day Entecavir, developed resistance over a median
follow up of 11 months. Of the four patients who received
0.5mg/day entecavir, one (25%) developed resistance over
follow up of 15 months.
Conclusions: Entecavir therapy in Lam resistant CHB
patients was associated with a high rate of inadequate
viral suppression and development of resistance. The dose
of Entecavir (0.5 or 1.0) did not seem to have much effect
in this group of patients.
PP-015 Management of chronic hepatitis B (CHB)
antiviral resistance the Asia experience
J. Cheng1, C.H. Lee2, T. Tanwandee3, J.C. Wu4, for The
Asia Paciﬁc Antiviral Resistance Project Study Group.
1Beijing Ditan Hospital, China, 2Konkuk University School
of Medicine, South Korea, 3Siriraj Hospital, Mahidol
University, Thailand, 4Veteran General Hospital Taipei,
Taiwan
Background: Resistance to CHB antivirals is a challenge
in the long term. Clinical beneﬁts are compromised once
resistance develops and cross-resistance limits treatment
options.
Methods: Current study randomly selected 575 CHB-treating
physicians from China, South Korea, Taiwan, and Thailand
where HBV infection is a substantial clinical and ﬁnancial
burden. The study comprised two components designed to
assess: (1) current practice in diagnosing antiviral resistance
and its management; and (2) ﬁnancial impact of managing
“suspected” resistance.
Results: 95 100% of interviewed physicians had encountered
antiviral resistance in the ﬁrst-line setting. Although 68%
agreed that prevention of resistance is the most important
strategy, 5% did not consider resistance a critical issue.
While direct antiviral resistance tests are readily available
in South Korea, access is limited in most Asian countries.
DNA and ALT tests are the common parameters used
to identify suspected resistance in China, Taiwan, and
Thailand. Management of suspected resistance (drug cost
not included) costs an additional USD 709, 580, 572 and 329
in South Korea, China, Taiwan and Thailand respectively,
during the ﬁrst year immediately after it is identiﬁed.
Conclusion: Antiviral resistance is a major concern among
physicians in Asia, especially during long-term therapy.
While access to direct resistance testing is limited in most
countries, indirect methods are widely used to guide CHB
management decisions. In choosing an oral antiviral to
initiate therapy, resistance proﬁle of antiviral is a crucial
factor to consider since drug resistance compromises clinical
beneﬁt and incurs additional cost.
PP-016 Effects of metabolic syndrome and related
factors in patients with chronic hepatitis B
J.Q. Zhang1 *, Y.Y. Cai1, W. Ling1, C.Y. Zhang1, X.G. Li2,
B. Li1, Q. Wang1, W.Y. Zhang1, X.L. Fan1, J. Cheng1.
1Institute of Infectious Diseases, Beijing Ditan Hospital,
Beijing, China, 2Department of Infectious Diseases, The
Second Afﬁliated Hospital, Harbin Medical University,
Harbin, China
Objective: The aim of this study is to investigate the
viral and host factors of metabolic syndrome in chronic
hepatitis B patients.
Methods: We studied 89 patients with untreated chronic
hepatitis B, who were from Beijing Ditan hospital in 2005 to
2007. According to the diagnose of metabolic syndrome, two
groups were established: group with MS (+MS) and group MS
( MS).They were compared with demographic, biochemical,
metabolic and histological characteristics.
Results: The mean age, BMI and gender were not
statistically signiﬁcant difference (p > 0.05) between the
two groups. In the group of chronic hepatitis B with MS,
the levels of FINS, HOMA-IR, HOMA-b, TG, and the positivity
of HBeAg were signiﬁcantly higher than those in the group
without MS (P< 0.05. The degree of hepatosteasis in the
group with MS is signiﬁcantly more severe than that in the
group without MS (P< 0.001).
Conclusion: Metabolic syndrome in chronic hepatitis B
patients is closely correlated with insulin resistance and
glycometabolism, and less effect of viruses. That may be the
main characteristic of metabolism in patients chronically
infected with the hepatitis B virus.
PP-017 The research of the cloning characteristics of
the CDR3-distinct of the TCR Vbgene of the
CD8+T cell of the HBV infected person
Y.G. Song*, J.W. Huang, J.L. Zhang, X.Y. Song. Afﬁliated
Hospital of Bei Hua University, China
Objective: This paper is an attempt to do research on
the cloning characteristics of the CDR3-distinct of the TCR
Vbgene of the CD8+T cell of the HBV infected person.
Methods: The PCR approach of poly-primer is applied and
meanwhile the many pieces of the CDR3-distinct of the TCR
Vb gene are ampliﬁed. HR-Agarose Gel Electrophoresis is
employed to detect the cloning characteristics.
Result: The HBV infected person’s cloning of the TCR Vb9
and Vb14 of the CD8+T cell is obviously higher than the
normal control group (p < 0.01).
Conclusion: The HBV infected person has the cloning
changes of the TCR VbandVb14 of the CD8+T cell, which
have an effect on the mediating of the Liver Injury.
PP-018 HIV/Hepatitis B Co-infection among Nepal
MSM/W
S. lal Acharya1 *, A. Sitoula Trisuli Plus2, S. Lama2,
G. Maharjan3. 1White Feather Nepal, 2National Association
of PLHA in Nepal (NAP+N), 3Tribhuvan University,
Department of Heath and social science, Katmandu,
Nepal
HIV/AIDS is one of the most public health problems of
this century. Moreover, co-infection with the Hepatitis B
virus is likely to become a major health care catastrophe.
This study was carried out White Feather Nepal and
different 4 Laboratories with the objective to determine
HIV/Hepatitis B co-infection among 544 sexual minorities
from Katmandu including Men Sex workers, gay men and
transgender.
Methods: HIV status was determined both by Rapid and
ELISA techniques. HIV sero-positive samples were further
tested for Hepatitis B Surface Antigen (HBsAg) by ELISA.
Data obtained from laboratories ﬁndings and questionnaires
were statistically analyzed by using SPSS 11.5.
Results: Out of 544 HIV suspected individuals, 221 (40%)
were diagnosed as HIV positive, of which, 187 HIV positive
sera were tested for Hepatitis B. In HIV positive individuals,
sexual transmission was the most common route (77.4%),
followed by IDUs (12.2%). Of 187 HIV positive individuals,
15% were diagnosed to be co-infected with Hepatitis B.
Highest prevalence of HIV/Hepatitis B co-infection (46.4%)
was observed in age group 26 35 years, followed by 16 25
years and the co infection rate was found to be higher
(78.6%) in married individuals than in unmarried (17.9%).
Lower rate of co-infection (17.9%) was detected among the
individuals vaccinated against Hepatitis B than unvaccinated
(82.1%).
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Lesson learned/recommendation: In Nepal, 15% of HIV
positive individuals being co-infected with Hepatitis B is
a recent threat to the health authority since both the
infections share a similar route of transmission which may
contribute to the devastating AIDS epidemic. Hepatitis B
screening should be made mandatory for all HIV sero-
positive individuals.
PP-019 Intrahepatic expression of PD-1, PD-L1 and
PD-L2 in Chronic Hepatitis B patients
J. Chen*, M.D. Lan, X.J. Wu, G.Q. Wang. Department of
Infection Disease, Peking University First Hospital, Beijing
10034, China
Background: The dysfunction of T cells may represent
a mechanism of hepatitis B virus (HBV) persistence.
Programmed death-1 (PD-1) and its ligands, PD-L1/PD-L2,
are new members of CD28/B7 family, was reported to
transfer inhibitory signal, leading to the dysfunction of
T cells.
Methods and Patients: Immunohistochemical analysis of
tissue samples from 56 patients with chronic hepatitis B
(CHB), 12 acute hepatitis B (AHB) patients and 10 health
controls was performed.
Results: PD-1 was positively expressed in inﬂammatory cells
inﬁltrating the portal area dominantly. PD-L1 expression
was more extensive, apart from the in portal area,
also expressed on hepatocytes and sinusoidal endothelial
cells. PD-L2 mostly expressed on kupffer cells (KCs) and
dendritic cells (DCs) in portal area as well as interlobular.
The PD-1-, PD-L1-positive cells on lymphocytes inﬁltrating
portal area of CHB patients was 32.33%± 30.56% and
30.68%± 27.07% respectively, more than that of health
controls (2.68%± 2.37%, 5.3%± 5.62% p < 0.05) and that of
AHB patients (12%± 9.6%, 8.7%± 7.4% p < 0.05). The PD-
L2-positive cells on KCs and DCs in CHB patients was
much higher (6.57%± 7.21%) than that in AHB patients
(15.7%± 8.2%) and health controls (2.06%± 2.35%), p < 0.05.
According to the the severity of illness index, the PD-1,
PD-L1, and PD-L2 expression rate within CHB patients
was increase with the disease progression (p < 0.05). The
expression of PD-L1 in interlobular in CHB was assayed
also, in severity group the number of higher score was
more than that in mild groups. And the expression of PD-1
on lymphocytes was correlated positively both with ALT
(r = 0.484, p < 0.05) and AST (r = 0.721, p < 0.05), although
had not apparent correlation with plasma DNA.
Conclusion: Overexpression of PD-1 and PD-L within liver
might be involved in inhibiting the immune response and be
a mechanism of chronicity in HBV infection.
PP-020 Hepatic steatosis is associated with host
metabolic factors but not viral effect in Chinese
patients with chronic hepatitis B
M.D. Lan1 *, Z.W. Lang1, X.M. Wang2, R.F. Shi1, L. Sun1,
B. Shen1, L. Zhang1, W.B. Dao1, X.H. Shi1, Z.C. Ma1,
J. Cheng2. 1Department of Pathology, Beijing Ditan
Hospital, Beijing 100011, China, 2Department of
Hepatology, Beijing Ditan Hospital, Beijing 100011, China
Aims: To investigate the prevalence and the risk factors
of hepatic steatosis in Chinese patients with chronic
hepatitis B.
Methods: Patients infected with hepatitis B virus who
underwent liver biopsy were included. One hundred and
sixty-one patients with chronic hepatitis B were divided
into two groups depending on the presence or absence
of steatosis in liver biopsy specimens. The relationships
of steatosis and demographic, laboratory and histological
characteristics were evaluated. Liver necroinﬂammatory
activity and ﬁbrosis were evaluated according to the
Knodell and Ishak’s classiﬁcation, respectively. Detection
of HBsAg and HBcAg were performed in liver specimen
by immunohistochemistry. Logistic regression analysis was
applied to identify variables that were independently
associated with the presence of steatosis.
Results: Hepatic steatosis was present in 53 patients
with chronic hepatitis B (53/161, 32.9%). Steatosis was
predominantly macrovesicular (49/53, 92.4%). Steatosis
was associated with ages (P < 0.001), BMI (P < 0.001),
fasting blood sugar (P = 0.001), cholesterol (P = 0.011) and
triglyceride (P = 0.004). In the multivariate analysis both
BMI (P= 0.036) and cholesterol (P = 0.021) were independent
predictors of the presence of steatosis. No signiﬁcant
correlation was found with gender, ALT, AST, TBil, ALP,
GGT, HBeAg, hepatitis B viral load, and histological ﬁndings
between the two groups (P > 0.05). HBsAg and HBcAg were
also detected in hepatocytes contain fat vacuoles.
Conclusion: Hepatic steatosis is present in 32.9% of
patients with biopsy-proven chronic hepatitis B. Steatosis
is independently associated with ages, BMI, fasting blood
sugar, cholesterol and triglyceride, suggesting being as a
result of metabolic factors of the host rather than the
effect of viruses and it seems to have not impact the
necroinﬂammatory activity and ﬁbrosis.
PP-021 Effect of INF-g treating on PD-1 expression on
lymphocytes
J. Chen*, X.J. Wu, Y. Wang, G.Q. Wang. Department of
Infection Disease, Peking University First Hospital, Beijing
10034, China
Background: The dysfunction of T cells may represent
a mechanism of hepatitis B virus (HBV) persistence.
Programmed death-1 (PD-1) and its ligands, PD-L1/PD-L2,
are new members of CD28/B7 family, as co-stimulatory
molecules expressing on T cells and Antigen Present Cells
(APCs). Their engaging can downregulate the T cells
function, including proliferation, cytokines secretion and
cytotoxicity. In periphery blood, PD-1 was upreguated on
virus speciﬁc-T cells, leading to the impairment of T cells.
Blocking the PD-1/PD-L can improve the function of T cells.
Methods and Patients: 21 patients with chronic hepatitis B
(CHB) were treated by IFN-g (Pegintron, once a week,
0.5 or 1mg/kg/weight). The periphery blood were taken
at pretherpay, 4 weeks, 8 weeks, and 12 weeks.
Periphery blood mononuclear cells were isolated from fresh
heparinized blood by Ficoll-Hypaque (density:1.077 g/L)
density gradient centrifugation. The PD-1 expression on
lymphocytes was detected by ﬂow cytometry (FCM).
Results: The PD-1 expression on lymphocytes at pretherapy
was 14.47± 5.8%, at 4 weeks was 9.68± 3.75%, at 8 weeks
was 6.95± 2.39%, at 12 weeks was 6.08± 1.31% (p < 0.05).
Conclusion: Treatment of IFN-g can downregulate the PD-1
expression on lymphocytes. Say in other words, Treatment
of IFN-g can partially restore the function of T cells.
PP-022 Clinical study of JianpiQinghua prescription
combined with lamivudine to treat chronic
hepatitis B
C.F. Wang1 *, J.J. Chen1, G.W. Liu2. 1The 1st associated
Hospital of Henan College of Traditional Chinese Medicine,
Zhengzhou, China, 2Shanghai Pudong New Area Infectious
Diseases Hospital, Shanghai 201200, China
Objective: To evaluate the antiviral efﬁcacy of
JianpiQinghua Prescription Combined with Lamivudine to
treat chronic hepatitis B differentiated as syndrome type
of liver depression and spleen asthenia accompanied by
